EQS-Ad-hoc: SYNLAB AG / Key word(s): Delisting SYNLAB AG (“SYNLAB”; FSE: SYAB) has today signed a delisting agreement (“Delisting Agreement”) with Ephios Bidco GmbH, a subsidiary of Ephios Luxembourg S.à r.l., both holding companies controlled by investment funds advised by Cinven Limited.
Concurrently, Ephios BidCo GmbH announced its decision to make a public delisting acquisition offer to the shareholders of SYNLAB to acquire all shares outstanding of SYNLAB (“Offer”) not directly held by it. Ephios BidCo GmbH already holds approx. 86% of the voting rights in SYNLAB. The Offer will not be subject to any conditions. The Delisting Agreement provides that, subject to the review of the published offer document and within the scope of and in compliance with its legal obligations, SYNLAB will file an application for revocation of the admission of the SYNLAB shares to trading on the regulated market of the Frankfurt Stock Exchange prior to the expiry of the Acceptance Period. After the revocation of the listing has taken effect, SYNLAB's shares will no longer be admitted to trading and traded on a domestic regulated market or a comparable market abroad. End of Inside Information
31-May-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Language: | English |
Company: | SYNLAB AG |
Moosacher Straße 88 | |
80809 Munich | |
Germany | |
Phone: | +49 1701183753 |
E-mail: | ir@synlab.com |
Internet: | www.synlab.com/ |
ISIN: | DE000A2TSL71 |
WKN: | A2TSL7 |
Indices: | SDAX |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: | 1914941 |
End of Announcement | EQS News Service |
|
1914941 31-May-2024 CET/CEST
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.